Suven Life Sciences Ltd

Suven Life Sciences is engaged in providing building blocks (bulk actives, drug intermediates and speciality chemicals) for global life science companies.

Pros:
Company is virtually debt free.
Company is expected to give good quarter
Cons:
The company has delivered a poor growth of 5.39% over past five years.
Debtor days have increased from 49.78 to 82.62 days.

Peer Comparison Sector: Pharmaceuticals // Industry: Pharmaceuticals - Indian - Bulk Drugs

Loading peers table ...

Quarterly Results Standalone Figures in Rs. Crores / View Consolidated

Dec 2016 Mar 2017 Jun 2017 Sep 2017 Dec 2017 Mar 2018 Jun 2018 Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019
116 180 141 107 164 214 192 90 129 253 199 274
79 132 96 62 112 122 133 65 93 148 109 164
Operating Profit 37 48 45 45 51 91 58 24 36 105 90 111
OPM % 32% 27% 32% 42% 31% 43% 30% 27% 28% 42% 45% 40%
Other Income 5 5 6 5 3 9 8 7 6 4 3 6
Interest 1 2 1 1 1 1 1 1 1 2 1 2
Depreciation 5 7 5 5 5 5 6 6 6 5 6 6
Profit before tax 36 44 44 44 48 94 60 25 35 102 86 109
Tax % 32% 10% 33% 28% 28% 33% 35% 28% 28% 33% 34% 33%
Net Profit 24 40 30 32 35 63 39 18 25 68 57 72
EPS in Rs 1.90 3.17 2.32 2.49 2.72 4.91 3.05 1.41 1.98 5.34 4.49 5.68
Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes Notes

Profit & Loss Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 TTM
117 140 129 150 204 258 510 521 499 543 625 663 856
105 122 116 137 181 205 291 361 369 378 392 440 514
Operating Profit 13 17 13 14 23 53 219 159 130 165 233 224 341
OPM % 11% 12% 10% 9% 11% 21% 43% 31% 26% 30% 37% 34% 40%
Other Income 3 -1 0 1 2 1 3 9 19 21 23 24 18
Interest 5 7 5 6 10 14 11 5 6 6 5 4 5
Depreciation 4 5 5 5 6 8 9 12 18 21 21 22 22
Profit before tax 6 5 4 3 9 33 203 152 126 159 230 222 332
Tax % -32% -40% -89% -219% -57% 6% 29% 28% 20% 23% 31% 32%
Net Profit 8 7 7 10 14 31 144 109 100 123 158 150 223
EPS in Rs 0.68 0.57 0.56 0.85 1.18 2.64 12.34 8.54 7.86 9.70 12.45 11.79 17.49
Dividend Payout % 35% 41% 41% 28% 24% 11% 20% 7% 25% 10% 12% 13%
* Sales is net of excise duty and discounts
Compounded Sales Growth
10 Years:16.84%
5 Years:5.39%
3 Years:9.93%
TTM:29.92%
Compounded Profit Growth
10 Years:26.98%
5 Years:-1.18%
3 Years:15.85%
TTM:44.65%
Stock Price CAGR
10 Years:25.04%
5 Years:3.93%
3 Years:13.93%
1 Year:14.73%
Return on Equity
10 Years:19.21%
5 Years:17.18%
3 Years:16.20%
Last Year:14.61%

Balance Sheet Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Sep 2019
12 12 12 12 12 12 12 13 13 13 13 13 13
Reserves 101 103 106 115 116 143 253 547 611 719 854 981 1,110
Borrowings 55 43 50 66 98 117 91 109 83 71 34 38 87
59 53 61 54 85 82 134 108 107 122 147 156 186
Total Liabilities 226 211 229 247 310 354 489 776 813 925 1,048 1,187 1,396
110 112 110 106 132 162 179 172 305 306 308 293 284
CWIP 4 4 3 3 24 4 13 107 7 10 25 111 138
Investments 8 6 12 20 5 0 0 0 23 366 381 366 502
104 89 105 117 150 188 297 497 477 243 334 417 472
Total Assets 226 211 229 247 310 354 489 776 813 925 1,048 1,187 1,396

Cash Flows Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
4 34 13 5 34 31 121 143 90 147 105 76
-16 -15 -10 -12 -32 -15 -36 -110 -62 -353 -38 -62
6 -21 -2 8 -2 3 -38 179 -68 -30 -52 -23
Net Cash Flow -7 -2 1 1 -0 19 47 212 -40 -236 15 -8

Ratios Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
ROCE % 7% 11% 5% 5% 9% 19% 68% 31% 17% 19% 25% 21%
Debtor Days 110 56 92 76 45 34 47 28 39 31 36 83
Inventory Turnover 4.96 5.42 4.47 4.71 5.11 5.14 7.71 6.49 6.04 6.17 5.39 4.47